dalteparin has been researched along with Peripheral Vascular Diseases in 9 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| "Sickle cell disease is one of the most common and severe genetic disorders in the world." | 2.52 | Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. ( Fedorowicz, Z; van Zuuren, EJ, 2015) |
| "Sickle cell disease is one of the most common and severe genetic disorders in the world." | 2.49 | Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. ( Fedorowicz, Z; van Zuuren, EJ, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mazzone, A | 1 |
| Giani, L | 1 |
| Faggioli, P | 1 |
| Pichini, S | 1 |
| Pacifici, R | 1 |
| Neagu, M | 1 |
| Manda, G | 1 |
| Constantin, C | 1 |
| Tanaseanu, C | 1 |
| Mikhailidis, DP | 1 |
| Schweizer, J | 1 |
| Müller, A | 1 |
| Forkmann, L | 1 |
| Hellner, G | 1 |
| Kirch, W | 1 |
| Kargin, VD | 1 |
| Rzhevskaia, VN | 1 |
| Saltykova, NB | 1 |
| Kapustin, SI | 1 |
| Papaian, LP | 1 |
| Norgren, L | 1 |
| Fazel, R | 1 |
| Froehlich, JB | 1 |
| Williams, DM | 1 |
| Saint, S | 1 |
| Nallamothu, BK | 1 |
| van Zuuren, EJ | 2 |
| Fedorowicz, Z | 2 |
| Koppensteiner, R | 1 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Rousson, V | 1 |
| Banyai, M | 1 |
| van der Loo, B | 1 |
2 reviews available for dalteparin and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Pain Measure | 2015 |
Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.
Topics: Anemia, Sickle Cell; Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Peripheral Vascular Dise | 2013 |
3 trials available for dalteparin and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive | 2001 |
Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? An open label prospective randomized controlled trial.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Logistic Models; Male; Peripheral Vascula | 2004 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
4 other studies available for dalteparin and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
Topics: Acute Disease; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anticoag | 2007 |
The in vitro effect of a low molecular weight heparin, nadroparin (Fraxiparine), on leukocytes obtained from patients with vascular diseases.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Abdominal; Dose-Response Relationship, Drug; Humans; Leukocyt | 2001 |
[Fraxiparin in the treatment of thrombophilia in angiopathy].
Topics: Adult; Anticoagulants; Female; Humans; Male; Middle Aged; Nadroparin; Peripheral Vascular Diseases; | 2001 |
Clinical problem-solving. A sinister development--a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma.
Topics: Adult; Anticoagulants; Constriction, Pathologic; Contraceptives, Oral; Edema; Enoxaparin; Female; Fi | 2007 |